Want to see PHIO full AI Analyst Report?
PHIO Stock Chart & Stats
$1.04
-$0.03(-2.80%)
At close: 4:00 PM EDT
$1.04
-$0.03(-2.80%)
Day’s Range― - ―
52-Week Range$0.81 - $4.19
Previous CloseN/A
Volume85.11K
Average Volume (3M)1.12M
Market Cap
$12.66M
Enterprise Value-$1.09
Total Cash (Recent Filing)$13.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Nov 05, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding11,617,250
10 Day Avg. Volume2,961,356
30 Day Avg. Volume1,116,732
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 1b data showed a high rate of pathologic responses in treated cutaneous skin cancer patients, including multiple complete clearances, indicating meaningful anti-tumor activity for PH-762.
Regulatory PathwayPlanned engagement with the FDA to define next clinical steps could clarify the development pathway and improve commercial visibility for the INTASYL delivery platform.
Safety ProfilePH-762 exhibited a consistent safety profile with no dose-limiting toxicities or serious treatment-related adverse events reported, supporting continued clinical evaluation.
Bears Say
Data MaturityCurrent findings are preliminary and require additional data to confirm durability of responses and applicability across broader patient populations.
Development RiskPH-762 remains in early clinical development, which creates substantial uncertainty around long-term outcomes and the likelihood of regulatory approval.
Phio Pharmaceuticals News
PHIO FAQ
What was Phio Pharmaceuticals’s price range in the past 12 months?
Phio Pharmaceuticals lowest stock price was $0.81 and its highest was $4.19 in the past 12 months.
What is Phio Pharmaceuticals’s market cap?
Phio Pharmaceuticals’s market cap is $12.66M.
When is Phio Pharmaceuticals’s upcoming earnings report date?
Phio Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 84 days.
How were Phio Pharmaceuticals’s earnings last quarter?
Phio Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.36 earnings per share for the quarter, the consensus estimate of -$0.36 by $0.
Is Phio Pharmaceuticals overvalued?
According to Wall Street analysts Phio Pharmaceuticals’s price is currently Overvalued.
Does Phio Pharmaceuticals pay dividends?
Phio Pharmaceuticals does not currently pay dividends.
What is Phio Pharmaceuticals’s EPS estimate?
Phio Pharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Phio Pharmaceuticals have?
Phio Pharmaceuticals has 11,617,250 shares outstanding.
What happened to Phio Pharmaceuticals’s price movement after its last earnings report?
Phio Pharmaceuticals reported an EPS of -$0.36 in its last earnings report, expectations of -$0.36. Following the earnings report the stock price went down -1.887%.
Which hedge fund is a major shareholder of Phio Pharmaceuticals?
Currently, no hedge funds are holding shares in PHIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Phio Pharmaceuticals
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Technical Analysis
Ownership Overview
6.07% Insiders
2.23% Mutual Funds
<0.01% Other Institutional Investors
90.88% Public Companies and
Individual Investors